Jump to content

Jeffery D. Molkentin

From Wikipedia, the free encyclopedia
(Redirected from Draft:Jeffery D. Molkentin)
Jeffery Daniel Molkentin
Born (1967-01-15) January 15, 1967 (age 57)
Alma materMarquette University
Scientific career
FieldsMolecular biology

Jeffery Daniel Molkentin (born January 15, 1967, in Milwaukee, Wisconsin) is an American molecular biologist.[1] He is the director of Molecular Cardiovascular Biology for Cincinnati Children's hospital where he is also co-director of their Heart Institute.[2] Molkentin holds a professorship at the University of Cincinnati's Department of Pediatrics.[3][4]

Biography

[edit]

Molkentin was born and raised in Milwaukee, Wisconsin.,[1] where he attended Marquette University, receiving a B.S. in biology in 1989. He began studies to be a medical doctor at the University of Wisconsin,[2] but switched to a research program, and received his PhD in physiology from the Medical College of Wisconsin in 1994.[1]

Molkentin's work focuses on heart disease and muscular dystrophy, though he is involved in other types of research entailing calcium handling, ER stress signaling, cardiac hypertrophic signaling pathways,[5] and COVID-19 disease mechanisms.[6] One of Molkentin's most notable research achievements was his contribution to stem cell therapy in the heart and his disproving prior research about the topic.[7][8]

Molkentin is among the most highly cited researchers in the world, with a Scopus h-index of 130 and a Google Scholar h-index of 156.[9][10] Molkentin is ranked 170th most cited Biology and Biochemistry researcher out of 30,000 scientists in the Research.com database.[11] His work has been published in several prestigious research journals, including "Nature",[12] "PNAS",[13] "Circulation Research",[14] and "Cell".[15]

Molkentin was a full investigator for the Howard Hughes Medical Institute (HHMI) from 2008 to 2021.[16]

Awards and honors

[edit]

Selected publications

[edit]

References

[edit]
  1. ^ a b c "Jeffery D. Molkentin | Science History Institute | Center for Oral History". oh.sciencehistory.org. Retrieved 2021-01-03.
  2. ^ a b "Jeffery D. Molkentin biography and affiliation".
  3. ^ "Cancer Biology Directory | Molgen | UC Cincinnati College of Medicine". Default. Retrieved 2021-01-02.
  4. ^ "Jeffery Molkentin, PhD | Jain Foundation". www.jain-foundation.org. Retrieved 2021-01-03.
  5. ^ "Regulation of Cardiac Hypertrophy | Molkentin Lab". www.cincinnatichildrens.org. Retrieved 2021-01-03.
  6. ^ "Cincinnati Children's launches six Covid-specific research projects". www.bizjournals.com. Retrieved 2021-01-03.
  7. ^ Huynh, Karina (February 2020). "Stem cell therapy improves heart function by triggering an acute immune response". Nature Reviews Cardiology. 17 (2): 69. doi:10.1038/s41569-019-0327-6. ISSN 1759-5010. PMID 31827260.
  8. ^ Johnson, Carolyn Y. "Benefits of stem cell heart therapy may have nothing to do with stem cells, a study on mice suggests". Washington Post. ISSN 0190-8286. Retrieved 2021-01-03.
  9. ^ "Scopus preview - Molkentin, Jeffery D. - Author details - Scopus". www.scopus.com. Retrieved 2023-12-24.
  10. ^ "Jeffery D Molkentin". scholar.google.com. Retrieved 2021-01-02.
  11. ^ "research.com molkentin ranking". research.com.
  12. ^ Vagnozzi, Ronald J.; Maillet, Marjorie; Sargent, Michelle A.; Khalil, Hadi; Johansen, Anne Katrine Z.; Schwanekamp, Jennifer A.; York, Allen J.; Huang, Vincent; Nahrendorf, Matthias; Sadayappan, Sakthivel; Molkentin, Jeffery D. (January 2020). "An acute immune response underlies the benefit of cardiac stem cell therapy". Nature. 577 (7790): 405–409. doi:10.1038/s41586-019-1802-2. ISSN 1476-4687. PMC 6962570.
  13. ^ Karch, J.; Molkentin, J. D. (2014-07-07). "Identifying the components of the elusive mitochondrial permeability transition pore". Proceedings of the National Academy of Sciences. 111 (29): 10396–10397. Bibcode:2014PNAS..11110396K. doi:10.1073/pnas.1410104111. ISSN 0027-8424. PMC 4115577. PMID 25002521.
  14. ^ Williams Ruth (2014-01-17). "Jeffery Molkentin". Circulation Research. 114 (2): 239–241. doi:10.1161/CIRCRESAHA.113.303225. PMID 24436426.
  15. ^ Davis, Jennifer; Davis, L. Craig; Correll, Robert N.; Makarewich, Catherine A.; Schwanekamp, Jennifer A.; Moussavi-Harami, Farid; Wang, Dan; York, Allen J.; Wu, Haodi; Houser, Steven R.; Seidman, Christine E.; Seidman, Jonathan G.; Regnier, Michael; Metzger, Joseph M.; Wu, Joseph C. (2016-05-19). "A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy". Cell. 165 (5): 1147–1159. doi:10.1016/j.cell.2016.04.002. ISSN 1097-4172. PMC 4874838. PMID 27114035.
  16. ^ "Jeffery D. Molkentin". HHMI.org. Retrieved 2021-01-02.
  17. ^ "Jeffery D. Molkentin, Ph.D." miRagen Therapeutics, Inc. Retrieved 2021-01-03.
  18. ^ a b Ince Susan (2015-08-28). "2015 Lucian Award". Circulation Research. 117 (6): 498–501. doi:10.1161/CIRCRESAHA.115.307326. PMID 26316606.
  19. ^ "Cincinnati Children's scientist lands $1M for 'revolutionary' heart research". www.bizjournals.com. Retrieved 2021-01-03.
  20. ^ "Jeffery D. Molkentin Ph.D." American Heart Association. Retrieved 2021-01-03.